Starpharma to present at OTCQX Virtual Investor Conference
Starpharma (ASX: SPL, OTCQX: SPHRY) today announced that as part of its OTCQX investor communications, a pre-recorded presentation by Chief Executive Officer Dr Jackie Fairley will be broadcast at VirtualInvestorConferences.com on Thursday 12 April 2018 at 10:30am (US ET time).
Starpharma on CommSec’s The Executive Series
|
Starpharma CEO Dr Jackie Fairley speaks with CommSec’s Tom Piotrowski about the Company’s performance since March 2017, its partnership with AstraZeneca and upcoming milestones. To view the video, click here |
Starpharma CEO Dr Jackie Fairley on Channel 9’s The Today Show for International Women’s Day
|
As part of International Women’s Day, Starpharma CEO Dr Jackie Fairley appeared with the Federal Minister for Women Kelly O’Dwyer and Today Show presenter Georgie Gardiner to discuss women in the workforce and gender equality. To view the video, click here. |
Starpharma Interim Report and Half-Year Financial Results
Starpharma today released its interim report and financial results for the half-year ended 31 December 2017.
Starpharma receives $3.7M R&D tax incentive refund
Starpharma today announced that it has received a $3.7M R&D tax incentive refund associated with FY17 expenditures. The refund relates to eligible R&D expenditure across Starpharma’s portfolio, including VivaGel® and DEP® programs.
Shareholder Update February 2018
In this issue:
>> New sites open for the DEP® docetaxel phase 2 trial
>> DEP® cabazitaxel phase 1 / 2 trial commences
>> VivaGel® BV NDA submission lodged under Fast Track program
>> VivaGel® BV approved by TGA
>> DEP® irinotecan progressing towards the clinic
>> AstraZeneca-Starpharma collaboration
>> Extensive global licensing negotiations for VivaGel® BV
>> Positive market research findings for VivaGel® BV
>> Q2 Cashflow Report at 31 December 2017
>> OTCQX market recognition
>> Starpharma News & Events
>> Outlook
Download: Shareholder Update February 2018 (pdf file, 1.5mb)
Starpharma announces DEP cabazitaxel Phase 1/2 Trial
Morningstar reported on Starpharma's announcement regarding the commencement of its phase 1/2 clinical trial for DEP cabazitaxel having received regulatory and ethics approvals.
Starpharma to commence DEP® cabazitaxel phase 1/2 trial
Starpharma today announced that it has received regulatory and ethics approvals to commence its phase 1/2 clinical trial for DEP® cabazitaxel. The objectives of the trial are to evaluate the safety, tolerability and pharmacokinetics of DEP® cabazitaxel, to define a recommended phase 2 dose (RP2D), and then to determine anti-tumour efficacy of the product in select tumour types.
Appendix 4C - Quarterly Cashflow Report
Starpharma (ASX: SPL, OTCQX: SPHRY) released its Appendix 4C – Quarterly Cashflow Report for the period ended 31 December 2017.
AstraZeneca plans to make better use of Australia’s innovation
|
The Australian highlighted Starpharma’s partnership with global pharmaceutical company AstraZeneca, noting the application of Starpharma’s DEP® technology platform helps make cancer drugs more effective, more patient-friendly and less toxic. |